Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 1

Status

Completed 49Terminated 23Active not recruiting 19Recruiting 18Withdrawn 6Unknown 5Suspended 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 4Thoracic 1

Conditions

Melanoma 4Recurrence 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1

Interventions

Cisplatin 512Radiotherapy 376Cyclophosphamide 361Carboplatin 354Capecitabine 341Oxaliplatin 331Paclitaxel 328Gemcitabine 318Docetaxel 314Fluorouracil 288Drug Therapy 271apatinib 245Bevacizumab 243camrelizumab 217Etoposide 200Irinotecan 182Doxorubicin 180Leucovorin 160Dexamethasone 160pembrolizumab 150sintilimab 143Neoadjuvant Therapy 142anlotinib 139Pemetrexed 138Cytarabine 138Blood Specimen Collection 138Surgical Procedures, Operative 130toripalimab 128Radiosurgery 127S 1 (combination) 124

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Unknown × binimetinib × Clear all
NCT04720768 2024-01-05

CELEBRATE

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Unknown
78 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT05767879 2023-03-14

(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

Leiden University Medical Center

Phase 2 Unknown
28 enrolled
Dermatologic

Melanoma

NCT05103891 2021-12-01

Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

Pierre Fabre Medicament

Phase 1 Unknown
14 enrolled
Dermatologic

Melanoma

NCT05097378 2021-10-28

PREMIUM

Cambridge University Hospitals NHS Foundation Trust

Phase 2 Unknown
45 enrolled
Dermatologic

Melanoma, Neoplasms

NCT04292119 2021-03-10

Lorlatinib Combinations in Lung Cancer

Massachusetts General Hospital

Phase 1/2 Unknown
96 enrolled
Thoracic

Lung Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡